Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Tildrakizumab is recommended as an option for treating plaque psoriasis in adults, only if:
• the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
• the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
• the company provides the drug according to the commercial arrangement.